GENOWAY SA (ALGEN.PA) Stock Price & Overview
EPA:ALGEN • FR0004053510
Current stock price
The current stock price of ALGEN.PA is 2.5 EUR. Today ALGEN.PA is down by 0%. In the past month the price decreased by -0.79%. In the past year, price decreased by -11.03%.
ALGEN.PA Key Statistics
- Market Cap
- 31.75M
- P/E
- 16.67
- Fwd P/E
- N/A
- EPS (TTM)
- 0.15
- Dividend Yield
- N/A
ALGEN.PA Stock Performance
ALGEN.PA Stock Chart
ALGEN.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALGEN.PA. When comparing the yearly performance of all stocks, ALGEN.PA is a bad performer in the overall market: 83.84% of all stocks are doing better.
ALGEN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALGEN.PA. Both the profitability and the financial health of ALGEN.PA get a neutral evaluation. Nothing too spectacular is happening here.
ALGEN.PA Earnings
ALGEN.PA Forecast & Estimates
9 analysts have analysed ALGEN.PA and the average price target is 4.49 EUR. This implies a price increase of 79.52% is expected in the next year compared to the current price of 2.5.
ALGEN.PA Groups
Sector & Classification
ALGEN.PA Financial Highlights
Over the last trailing twelve months ALGEN.PA reported a non-GAAP Earnings per Share(EPS) of 0.15. The EPS increased by 5.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.14% | ||
| ROA | 3.31% | ||
| ROE | 7% | ||
| Debt/Equity | 0.71 |
ALGEN.PA Ownership
ALGEN.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.71 | 42.625B | ||
| 1AE | ARGENX SE | 29.52 | 42.6B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.126B | ||
| ABVX | ABIVAX SA | N/A | 7.766B | ||
| 2X1 | ABIVAX SA | N/A | 7.747B | ||
| GLPG | GALAPAGOS NV | N/A | 1.629B | ||
| GXE | GALAPAGOS NV | N/A | 1.628B | ||
| NANO | NANOBIOTIX | N/A | 1.392B | ||
| PHARM | PHARMING GROUP NV | 46.9 | 1.025B | ||
| PHGN | PHARMING GROUP NV | 47.72 | 1.021B | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| IVA | INVENTIVA SA | N/A | 934.695M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALGEN.PA
Company Profile
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
Company Info
IPO: 2007-05-04
GENOWAY SA
Technopark 2, 31 Rue Saint Jean-de-Dieu
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 148
Phone: 33437654100
GENOWAY SA / ALGEN.PA FAQ
Can you describe the business of GENOWAY SA?
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
What is the stock price of GENOWAY SA today?
The current stock price of ALGEN.PA is 2.5 EUR.
What is the dividend status of GENOWAY SA?
ALGEN.PA does not pay a dividend.
How is the ChartMill rating for GENOWAY SA?
ALGEN.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ALGEN stock to perform?
9 analysts have analysed ALGEN.PA and the average price target is 4.49 EUR. This implies a price increase of 79.52% is expected in the next year compared to the current price of 2.5.
Would investing in GENOWAY SA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALGEN.PA.